newsfilter
← Latest News
ACCESS Newswire·

Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results

Net income of $1.5 millionAdjusted EBITDA1 of $1.9 millionADHD Portfolio net revenue up 1% to $15.3 millionPediatric Portfolio net revenue up 54% sequentially$20.1 million cash balance at September 30, 2024Organizational